It might identify subtle alterations in cancer-associated DNA sequences and target mutations in genes such as BRCA1/BRCA2, thereby facilitating early and precise detection in liquid biopsy samples, providing robust support for early breast cancer screening and corrective diagnosis. This evidence concerns the gene BRCA1 and breast carcinoma.